[{sup 18}F]FDG-Positron Emission Tomography Coregistration With Computed Tomography Scans for Radiation Treatment Planning of Lymphoma and Hematologic Malignancies

Journal Article · Tue Nov 01 00:00:00 EDT 2011 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2010.06.044· OSTI ID:21590411

Terezakis, Stephanie A ^[1]; Hunt, Margie A; Kowalski, Alexander; McCann, Patrick ^[2]; Schmidtlein, C Ross ^[3]; Reiner, Anne; Goenen, Mithat ^[4]; Kirov, Assen S ^[2]; Gonzales, Anne Marie ^[1]; Schoeder, Heiko ^[3]; Yahalom, Joachim ^[1]

---

1. Department of Radiation Oncology Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York (United States)
2. Department of Radiology, Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York (United States)
3. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York (United States)
4. Memorial Sloan-Kettering Cancer Center, New York, New York (United States)

Purpose: Positron emission-tomography (PET) using 2-[{sup 18}F]fluoro-2-deoxyglucose (FDG-PET) increases sensitivity and specificity of disease detection in lymphoma and thus is standard in lymphoma management. This study examines the effects of coregistering FDG-PET and computed tomography (CT) (PET/CT) scans on treatment planning for lymphoma patients. Methods and Materials: Twenty-nine patients (30 positive PET scans) underwent PET/CT treatment planning from July 2004 to February 2007 and were retrospectively studied. For each patient, gross tumor volume was blindly contoured on the CT-only and PET/CT studies by a radiation oncologist. Treatment plans were generated for both the CT-only and PET/CT planning target volumes (PTVs) for all patients. Normal tissue doses and PTV coverage were evaluated using dose--volume histograms for all sites. Results: Thirty-two treatment sites were evaluated. Twenty-one patients had non-Hodgkin lymphoma, 5 patients had Hodgkin lymphoma, and 3 patients had plasma cell neoplasms. Previously undetected FDG-avid sites were identified in 3 patients during PET/CT simulation, resulting in one additional treatment field. Due to unexpected PET/CT simulation findings, 2 patients did not proceed with radiation treatment. The addition of PET changed the volume of 23 sites (72%). The PTV was increased in 15 sites (47%) by a median of 11% (range, 6-40%) and reduced in 8 sites (25%) by a median of 20% (range, 6%-75%). In six (19%) replanned sites, the CT-based treatment plan would not have adequately covered the PTV defined by PET/CT. Conclusions: Incorporation of FDG-PET into CT-based treatment planning for lymphoma patients resulted in considerable changes in management, volume definition, and normal tissue dosimetry for a significant number of patients.

• OSTI ID: 21590411
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Vol. 81, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2010.06.044; PII: S0360-3016(10)00895-3; Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
CAT SCANNING
DOSIMETRY
FLUORINE 18
LYMPHOMAS
PLASMA CELLS
POSITRON COMPUTED TOMOGRAPHY
RADIATION DOSES
SENSITIVITY
SIMULATION
SPECIFICITY
ANIMAL CELLS
BETA DECAY RADIOISOTOPES
BETA-PLUS DECAY RADIOISOTOPES
COMPUTERIZED TOMOGRAPHY
CONNECTIVE TISSUE CELLS
DIAGNOSTIC TECHNIQUES
DISEASES
DOSES
EMISSION COMPUTED TOMOGRAPHY
FLUORINE ISOTOPES
HOURS LIVING RADIOISOTOPES
IMMUNE SYSTEM DISEASES
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
LIGHT NUCLEI
NANOSECONDS LIVING RADIOISOTOPES
NEOPLASMS
NUCLEI
ODD-ODD NUCLEI
RADIOISOTOPES
SOMATIC CELLS
TOMOGRAPHY